PDCD1 and urinary bladder carcinoma: and bladder cancer anti-PD-1 therapy cohort (IMvigor210), we classified patients into four subtypes that showed consistent patterns of immune and metabolic activities (Figures 5A, B; Supplementary Figures S6A, B).